157 related articles for article (PubMed ID: 26973260)
1. Plasma Levels of Receptor for Advanced Glycation End-Products and High-Mobility Group Box 1 in Patients With Pulmonary Hypertension.
Suzuki S; Nakazato K; Sugimoto K; Yoshihisa A; Yamaki T; Kunii H; Suzuki H; Saitoh S; Takeishi Y
Int Heart J; 2016; 57(2):234-40. PubMed ID: 26973260
[TBL] [Abstract][Full Text] [Related]
2. Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure.
Basta G; Del Turco S; Navarra T; Lee WM;
Liver Transpl; 2015 Jun; 21(6):847-54. PubMed ID: 25825217
[TBL] [Abstract][Full Text] [Related]
3. Potential of Receptor for Advanced Glycation End-Products (RAGE) as an Eligible Biomarker for Therapy Evaluation in Patients With Pulmonary Hypertension.
Hatano M
Int Heart J; 2016; 57(2):132-3. PubMed ID: 26973280
[No Abstract] [Full Text] [Related]
4. Soluble RAGE and the RAGE ligands HMGB1 and S100A12 in critical illness: impact of glycemic control with insulin and relation with clinical outcome.
Ingels C; Derese I; Wouters PJ; Van den Berghe G; Vanhorebeek I
Shock; 2015 Feb; 43(2):109-16. PubMed ID: 25394242
[TBL] [Abstract][Full Text] [Related]
5. Members of the receptor for advanced glycation end products axis as potential therapeutic targets in patients with lupus nephritis.
Yu SL; Wong CK; Szeto CC; Li EK; Cai Z; Tam LS
Lupus; 2015 Jun; 24(7):675-86. PubMed ID: 25411258
[TBL] [Abstract][Full Text] [Related]
6. Soluble Forms and Ligands of the Receptor for Advanced Glycation End-Products in Patients with Acute Respiratory Distress Syndrome: An Observational Prospective Study.
Jabaudon M; Blondonnet R; Roszyk L; Pereira B; Guérin R; Perbet S; Cayot S; Bouvier D; Blanchon L; Sapin V; Constantin JM
PLoS One; 2015; 10(8):e0135857. PubMed ID: 26274928
[TBL] [Abstract][Full Text] [Related]
7. Low glucose degradation product peritoneal dialysis regimen is associated with lower plasma EN-RAGE and HMGB-1 proinflammatory ligands of receptor for advanced glycation end products.
Opatrna S; Popperlova A; Kalousová M; Zima T
Ther Apher Dial; 2014 Jun; 18(3):309-16. PubMed ID: 24965297
[TBL] [Abstract][Full Text] [Related]
8. Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients.
Tang KT; Hsieh TY; Chao YH; Lin MX; Chen YH; Chen DY; Lin CC
PLoS One; 2017; 12(5):e0178404. PubMed ID: 28558055
[TBL] [Abstract][Full Text] [Related]
9. Clinical use of high mobility group box 1 and the receptor for advanced glycation end products in the prognosis and risk stratification of heart failure: a literature review.
Marsh AM; Nguyen AH; Parker TM; Agrawal DK
Can J Physiol Pharmacol; 2017 Mar; 95(3):253-259. PubMed ID: 28092162
[TBL] [Abstract][Full Text] [Related]
10. Expression of HMGB1/RAGE protein in renal carcinoma and its clinical significance.
Qie GQ; Wang CT; Chu YF; Wang R
Int J Clin Exp Pathol; 2015; 8(6):6262-8. PubMed ID: 26261503
[TBL] [Abstract][Full Text] [Related]
11. Local and systemic RAGE axis changes in pulmonary hypertension: CTEPH and iPAH.
Moser B; Megerle A; Bekos C; Janik S; Szerafin T; Birner P; Schiefer AI; Mildner M; Lang I; Skoro-Sajer N; Sadushi-Kolici R; Taghavi S; Klepetko W; Ankersmit HJ
PLoS One; 2014; 9(9):e106440. PubMed ID: 25188497
[TBL] [Abstract][Full Text] [Related]
12. Decreased level of sRAGE in the cerebrospinal fluid of multiple sclerosis patients at clinical onset.
Glasnović A; Cvija H; Stojić M; Tudorić-Đeno I; Ivčević S; Romić D; Tičinović N; Vuletić V; Lazibat I; Grčević D
Neuroimmunomodulation; 2014; 21(5):226-33. PubMed ID: 24603633
[TBL] [Abstract][Full Text] [Related]
13. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients.
Fahmueller YN; Nagel D; Hoffmann RT; Tatsch K; Jakobs T; Stieber P; Holdenrieder S
Int J Cancer; 2013 May; 132(10):2349-58. PubMed ID: 23047645
[TBL] [Abstract][Full Text] [Related]
14. High-mobility group box-1 induces vascular remodelling processes via c-Jun activation.
Zabini D; Crnkovic S; Xu H; Tscherner M; Ghanim B; Klepetko W; Olschewski A; Kwapiszewska G; Marsh LM
J Cell Mol Med; 2015 May; 19(5):1151-61. PubMed ID: 25726846
[TBL] [Abstract][Full Text] [Related]
15. HMGB1/RAGE Signaling and Pro-Inflammatory Cytokine Responses in Non-HIV Adults with Active Pulmonary Tuberculosis.
Lui G; Wong CK; Ip M; Chu YJ; Yung IM; Cheung CS; Zheng L; Lam JS; Wong KT; Sin WW; Choi KW; Lee N
PLoS One; 2016; 11(7):e0159132. PubMed ID: 27434276
[TBL] [Abstract][Full Text] [Related]
16. Angiogenic and inflammatory biomarkers in the differentiation of pulmonary hypertension.
Säleby J; Bouzina H; Lundgren J; Rådegran G
Scand Cardiovasc J; 2017 Oct; 51(5):261-270. PubMed ID: 28776404
[TBL] [Abstract][Full Text] [Related]
17. Placental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: a cross sectional study.
Zakiyanov O; Kriha V; Vachek J; Zima T; Tesar V; Kalousova M
BMC Nephrol; 2013 Nov; 14():245. PubMed ID: 24188108
[TBL] [Abstract][Full Text] [Related]
18. Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome.
Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Maeda S; Yamagishi S
Clin Biochem; 2011 Jun; 44(8-9):601-4. PubMed ID: 21211520
[TBL] [Abstract][Full Text] [Related]
19. High motility group box 1 (HMGB1) protein and its receptor for advanced glycation end products (RAGE) expression in chronic rhinosinusitis without nasal polyps.
Dzaman K; Zagor M; Molinska-Glura M; Krzeski A
Folia Histochem Cytobiol; 2015; 53(1):70-8. PubMed ID: 25772690
[TBL] [Abstract][Full Text] [Related]
20. Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review.
Nguyen AH; Detty SQ; Agrawal DK
Anticancer Res; 2017 Jan; 37(1):1-7. PubMed ID: 28011467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
